|
- 现金
- 1401 元
- 精华
- 34
- 帖子
- 13714
- 注册时间
- 2002-5-19
- 最后登录
- 2014-1-20
|
hzhch 发表于 2011-4-22 20:42 
祝福你！ 昨天见到这则消息不知是否真假。常州晚报“万能”药物可治多种癌症
...
“据英国《每日邮报》4月15日报道，英国科学家近期研制出了一种“万能”药物，可用于治疗包括胰腺癌在内的多种癌症，并预计在两年后面世。”
--------------
http://www.dailymail.co.uk/health/article-1377069/Universal-cancer-vaccine-TeloVac-arrive-years.html
来源：英国2011年每日电讯报 4月15日。
----------
标题：
普便适用的抗癌药物：可以阻止所有肿瘤进展的疫苗可能在两年内出来。
'Universal' cancer jab: Vaccine that stops all tumours in their tracks could be here in two years
------
By Fiona Macrae
Last updated at 1:14 AM on 15th April 2011
------
以下内容为GOOGLE自动翻译， 未经纠错。
------
一个'普遍'疫苗，可以彻底改变癌症的治疗可以在短短两年内提供。
该TeloVac山是使用的药物人体自身的防御系统来对付这种疾病，肿瘤停止在其轨道上的新一代。
TeloVac已经给了与胰腺癌，对该病的最致命的形式之一英国人数百人。
但希望这将是对许多其他肿瘤，包括皮肤，肺和肝效益。乳腺癌和前列腺癌也可在其掌握。
总之，这种疾病的六种形式，超过70,000个索赔生活在英国的一年。
在胰腺癌，造成演员帕特里克斯韦兹的情况下，存活率几乎没有改善，在过去40年，患者通常在六个月内死亡诊断个月。
只有3生存百分之五年，是在英国第五大癌症杀手。虽然通常的疫苗预防疾病，TeloVac山被设计成一种治疗。
而不是攻击癌细胞，像许多现有的药物，它利用了免疫系统对抗肿瘤的能力。
它通过鼓励免疫系统去寻找和摧毁一种酶叫做端粒酶。在许多癌症细胞中找到高水平，端粒酶有效地使他们不朽，让他们过上健康的细胞时，会死 - 减轻肿瘤的生长和扩散。
在其在英国规模最大的试验，1000多名男女在胰腺癌晚期阶段的妇女要么正在考虑同时其正常的疫苗或药物像往常一样对待。
从参加的53个医院的结果将不会提供，但到明年，闲谈，一些患者在与他们的信贷给他们一个额外的一年或两年的生活参与试验。在早期，小试验，该疫苗在疾病了一个额外的三个月平均晚期的。
约翰Neoptolemos，谁是统筹大型英国审讯，说：'。当你拥有胰腺癌，它就像一个定时油油炸弹在人们是'
胰腺癌细胞通常是不可见的免疫系统，但该疫苗'点'的端粒酶溢出从他们踢，开始反击。
利物浦大学教授Neoptolemos，说：'这是免疫系统就像一个眼罩和疫苗取眼罩了。'
健康细胞的攻击，因为逃避端粒酶的水平太低，麻烦的免疫系统。这削减副作用，如恶心，通常与癌症的药物出现脱发的风险。
如果最新的研究，这是由英国癌症研究中心资助的，证明了山的价值，它可能是可以治疗由2013年底晚期胰腺癌。随着时间的推移，它可用于在疾病的早期 - 甚至加以预防。
周杰伦Sangjae博士金，对GemVax，韩国公司开发的TeloVac疫苗，创始人说：'我们坚信，这有可能克服目前的癌症疫苗的其他限制，成为标准的一部分的护理胰腺癌的不只是但各种其他类型的癌症。
'换句话说，一个真正的“万能”疫苗将在不久的将来提供。'
教授彼得约翰逊英国癌症研究中心，说：'我们饶有兴趣地等待着结果，看看这是否是一种有效的治疗。'
---------
'Universal' cancer jab: Vaccine that stops all tumours in their tracks could be here in two years
------
By Fiona Macrae
Last updated at 1:14 AM on 15th April 2011
------
A 'universal' vaccine that could revolutionise the treatment of cancer could be available in just two years.
The TeloVac jab is part of a new generation of drugs that use the body’s own defences to fight the disease, stopping tumours in their tracks.
TeloVac has already been given to hundreds of Britons with pancreatic cancer, one of the deadliest forms of the disease.
But it is hoped it will be effective against many other tumours, including those of the skin, lung and liver. Breast and prostate cancers may also be within its grasp.
Together, the six forms of the disease claim more 70,000 lives a year in the UK.
In the case of pancreatic cancer, which killed actor Patrick Swayze, survival rates have barely improved in the past 40 years, and patients typically die within six months of diagnosis.
Just 3 per cent survive five years, and it is the fifth biggest cancer killer in the UK. Although vaccines usually prevent disease, the TeloVac jab is designed as a treatment.
Rather than attacking the cancer cells, like many existing drugs, it harnesses the power of the immune system to fight the tumours.
It works by encouraging the immune system to seek out and destroy an enzyme called telomerase. Found at high levels in many cancer cells, telomerase effectively makes them immortal, allowing them to live on when healthy cells would die – easing the growth and spread of the tumour.
In the largest trial of its kind in the UK, more than 1,000 men and women in the late stages of pancreatic cancer are either being given the vaccine alongside their normal drugs or treated as usual.
The results from the 53 hospitals taking part will not be available until next year but, anecdotally, some patients credit their participation in the trial with giving them an extra year or two of life. In earlier, smaller trials, the vaccine gave those in the late stages of the disease an average of an extra three months.
John Neoptolemos, who is co-ordinating the large-scale British trial, said: ‘When you have got pancreatic cancer, it is like a timebomb in people.’
Pancreatic cancer cells are normally invisible to the immune system but the vaccine ‘spots’ the telomerase spilling out from them and kick-starts the fight back.
Professor Neoptolemos, of Liverpool University, said: ‘It is like the immune system has a blindfold on and the vaccine takes the blindfold off.’
Healthy cells escape the attack because their levels of telomerase are too low to bother the immune system. This cuts the risk of side-effects such as nausea and hair loss normally seen with cancer drugs.
If the latest study, which is funded by Cancer Research UK, proves the jab’s worth, it could be available to treat advanced pancreatic cancer by the end of 2013. In time, it could be used earlier in the disease – and even to prevent it.
Dr Jay Sangjae Kim, the founder of GemVax, the Korean company developing the TeloVac vaccine, said: ‘We strongly believe this has the potential to overcome the limits of other current cancer vaccines and become part of the standard of care not only for pancreatic cancer but for various other types of cancers.
‘In other words, a truly “universal” vaccine will be available in the near future.’
Professor Peter Johnson, of Cancer Research UK, said: ‘We await the results with interest to see if this is an effective treatment.’
|
|
楼主: linx
发表于 2011-4-23 00:32
